Wealth Enhancement Advisory Services LLC Buys 6,112 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Wealth Enhancement Advisory Services LLC raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 94.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,566 shares of the biopharmaceutical company's stock after purchasing an additional 6,112 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Alnylam Pharmaceuticals were worth $2,957,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Allworth Financial LP grew its stake in Alnylam Pharmaceuticals by 6.8% in the 4th quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company's stock worth $140,000 after acquiring an additional 38 shares in the last quarter. Investment Management Corp of Ontario grew its stake in Alnylam Pharmaceuticals by 0.6% in the 4th quarter. Investment Management Corp of Ontario now owns 7,099 shares of the biopharmaceutical company's stock worth $1,670,000 after acquiring an additional 40 shares in the last quarter. Nixon Peabody Trust Co. grew its stake in Alnylam Pharmaceuticals by 1.9% in the 4th quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company's stock worth $540,000 after acquiring an additional 43 shares in the last quarter. Brevan Howard Capital Management LP grew its stake in Alnylam Pharmaceuticals by 3.4% in the 4th quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company's stock worth $314,000 after acquiring an additional 44 shares in the last quarter. Finally, IFP Advisors Inc grew its stake in Alnylam Pharmaceuticals by 24.2% in the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock worth $57,000 after acquiring an additional 47 shares in the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Up 0.9%

Shares of ALNY traded up $2.69 during mid-day trading on Thursday, hitting $308.00. 761,194 shares of the company's stock were exchanged, compared to its average volume of 930,080. The firm has a fifty day moving average of $262.51 and a two-hundred day moving average of $256.16. Alnylam Pharmaceuticals, Inc. has a twelve month low of $147.25 and a twelve month high of $310.23. The stock has a market cap of $40.16 billion, a price-to-earnings ratio of -141.93 and a beta of 0.17. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The company had revenue of $594.19 million for the quarter, compared to analyst estimates of $584.32 million. The company's revenue was up 20.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.16) EPS. On average, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Activity at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 31,640 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, May 30th. The shares were sold at an average price of $304.39, for a total transaction of $9,630,899.60. Following the completion of the sale, the chief executive officer now owns 48,948 shares in the company, valued at $14,899,281.72. The trade was a 39.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

ALNY has been the topic of a number of recent research reports. Royal Bank of Canada increased their price objective on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an "outperform" rating in a research note on Friday, March 21st. Morgan Stanley dropped their price objective on shares of Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating on the stock in a research note on Friday, April 11th. UBS Group increased their price objective on shares of Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. HC Wainwright restated a "buy" rating and issued a $500.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 2nd. Finally, Bank of America raised their target price on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a "buy" rating in a research note on Friday, March 21st. One investment analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have issued a buy rating to the stock. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $319.17.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.